Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

The race to treat obesity with powerful new medicines has become one of the defining stories in global healthcare, and Novo ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

Once relegated to the fringes of lifestyle care, obesity drugs have emerged as one of the world's most powerful growth ...

US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

The FDA granted accelerated approval for the subcutaneous formulation of mosunetuzumab (Lunsumio VELO) for certain patients ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

In a significant development for global health, U.S. regulators have approved an oral version of the Wegovy weight-loss drug, marking the first time this powerful treatment will be available in pill ...